• Biosimilars
  • Drug Development/R&D
  • All Topics
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

Proposal for a General Outcome-based Value Attribution Framework for Combination Therapies

CombTher_Adobe_photoguns_portrait
Read more
© photoguns
  • Digital Health

Navigating the Landscape of Digital Health – United Kingdom

Healthcare_Adobe_elenabsl
Read more

2021 OHE Annual Report to the Charity Commission

charityreport_lina-trochez-unsplash_landscape
Read more
© Lina Trochez/Unsplash

Supporting the Era of Green Pharmaceuticals in the UK

Sustainability_AdobeStock_270582392_landscape
Read more

Quality of life and wellbeing in individuals with experience of fertility problems and assisted reproductive techniques

Quality of life assisted reproduction Cover
Read more
  • Cell and Gene Therapies
  • Value, Affordability, and…

Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose?

gene_therapies_national-cancer-institute-unsplash_landscape
Read more
© NCI/Unsplash
  • Drug Development/R&D
  • Economics of Innovation
  • Health Policy and Regulation

Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers

CBO-US_mayer-tawfik-K4Ckc0AxgDI-unsplash_landscape
Read more
© Mayer Tawfik/Unsplash
  • Measuring and Valuing Outcomes

When Generic Measures Fail to Reflect What Matters to Patients: Three Case Studies

PROMS_unsplash_National Cancer Institute_landscape
Read more
© NCI/Unsplash
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • News
11 min read 2nd May 2017

HTAi Asia Policy Forum Briefing Papers: Value and Affordability, Transferability, and Delivery of High Quality HTA for Decision Making

The fourth annual meeting of the HTAi Asia Policy Forum was held in November 2016. OHE produced Background Briefing Papers for each of these four meetings covering a variety of topics relevant to the development of HTA in Asia, all…

Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email

The fourth annual meeting of the HTAi Asia Policy Forum was held in November 2016. OHE produced Background Briefing Papers for each of these four meetings covering a variety of topics relevant to the development of HTA in Asia, all of which are now available. This post contains a summary of each report.

The fourth annual meeting of the Health Technology Assessment International (HTAi) Asia Policy Forum (HAPF) was held in November 2016. The HAPF meetings are attended by participants from: HTA and payer systems in Asian countries; pharmaceutical and medical device companies with interest and expertise in Asia; invited experts; and the organisers, and are designed to promote in-depth, open and constructive exchange between these stakeholder groups.

The OHE worked with HTAi, Chris Henshall, and the global pharmaceutical industry to establish the AHPF in 2013. OHE’s Adrian Towse and Grace Hampson provided the scientific secretariat for the first four of these meetings 2013-2016, working in close collaboration with HTAi and Chris Henshall, Chair of the HAPF 2013-2016. The chair and scientific secretariat from 2017 will come from the Asia-Pacific region.

The background papers for each of the 2013-2016 meetings are now available. A brief summary of each is provided below:

2016

The topic of the 2016 meeting was: Assessing Value, Budget Impact and Affordability to Inform Discussions on Access and Reimbursement: Principles and Practice, with Special Reference to High Cost Technologies.

The background paper begins with a discussion of how value can be defined, measured and factored into decisions on access and coverage.

Next, the paper looks at how budget impact and affordability can be defined and measured: we explain how different countries have adopted different approaches to how and when budget impact has been included within the decision making process, and outline several different scenarios around affordability challenges.

The final section considers whether high cost interventions call for new approaches to assessment and/or reimbursement, drawing on the recent high profile example of Sovaldi for the treatment of Hepatitis C.

2015

The topic of the 2015 meeting was: How can HTA meet the needs of health system and government decision makers?

The background paper sets out the issues to be addressed in considering where and when HTA could be a useful aid for decision making, what HTA can be used to achieve, and where the evidence for HTA can be obtained from (including a brief recap of the transferability discussions in the 2014 meeting of the AHPF).

The final section considers how decision makers can combine all the relevant criteria and information to arrive at a decision; we discuss the spectrum of approaches from deliberative to more structured decision making processes including the use of Multi-Criteria Decision Analysis (MCDA).

Various different approaches to MCDA could be used to add structure and transparency to decision making processes, and pilots conducted in Asia have been reported favourably. MCDA has not, however, been widely adopted in health care decision making to date.

2014

The 2014 meeting looked at: Transferability of HTA.

HTA is a tool to support health systems to make decisions about allocating their limited health care resources. In turn, HTA needs to be efficient and effective if investment in HTA is to be a sensible use of money. One important part of ensuring this will be to avoid duplication of effort by making the best possible use of existing information, and ensuring that when resources devoted to HTA are generating new information, it is likely to be of sufficient value to justify its cost.

This background paper sets out the issues to be addressed in considering when health systems can benefit from the transfer of HTA processes, decisions and/or data. We discuss the different kinds of decisions that may or may not be transferred, the different degrees of transfer possible, and how decisions can be adapted to different contexts.

Overall, we conclude that some of the barriers to transferability may be lower than is generally believed.

2013

The topic of the 2013 meeting was: How can the available resources be used most effectively to deliver high quality HTA that can be used by health system decision makers?

The background paper begins by looking at the increasing interest in the use of HTA, how HTA has evolved, where HTA has got to in Asia.

The report then seeks to address the follow questions:

  • What information do decision makers need?
  • How can HTA best meet these information needs?
  • How can HTA and decision making best be linked?

The report also includes short appendices which provide an overview of the use of HTA in each of the health systems represented at the meeting: China, Japan, Korea, Malaysia, Philippines, Singapore, Taiwan and Thailand.

  • Emerging Markets
  • Value, Affordability, and…
  • Briefing

Related News

  • News
  • September 2020

Cornerstones of ‘Fair’ Drug Coverage

Read more
  • News
  • September 2020

Establishing a Reasonable Price for an Orphan Drug

Read more
  • News
  • June 2020

The 2020 OHE Annual Lecture Explores the Question: How Should the World Pay for a COVID-19 Vaccine?

Read more
Danzon_Patricia_1305 (1)
  • News
  • June 2020

Victor R. Fuchs Award for 2020 Goes to Patricia Danzon

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!